Stevenson D D, Hougham A J, Schrank P J, Goldlust M B, Wilson R R
Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, La Jolla, Calif. 92037.
J Allergy Clin Immunol. 1990 Nov;86(5):749-58. doi: 10.1016/s0091-6749(05)80179-4.
Ten aspirin (ASA)-sensitive patients with asthma underwent double-blind, placebo-controlled oral challenges with salsalate followed by ASA-sensitive confirmatory challenges. All 10 patients sustained asthmatic reactions to ASA, but only two developed respiratory reactions to 2 gm of salsalate. In these two patients, repeat confirmatory challenges with 2 gm of salsalate reproduced the same asthmatic reactions. Both patients were desensitized to ASA, and cross-desensitization with 2 gm of salsalate was then achieved. We conclude that salsalate, a weak inhibitor of cyclooxygenase in vitro, is less likely than ASA to induce asthma in known ASA-sensitive patients with asthma but may occasionally cross-react in these patients. Such reactions were mild and easily treated with beta 2-agonists.
十名对阿司匹林(ASA)敏感的哮喘患者接受了双盲、安慰剂对照的口服水杨酸盐激发试验,随后进行了ASA敏感性确认激发试验。所有10名患者对ASA均出现哮喘反应,但只有两名患者对2克水杨酸盐出现呼吸道反应。在这两名患者中,用2克水杨酸盐重复进行确认激发试验再现了相同的哮喘反应。两名患者均对ASA进行了脱敏治疗,随后用2克水杨酸盐实现了交叉脱敏。我们得出结论,水杨酸盐在体外是一种弱环氧化酶抑制剂,与ASA相比,它在已知对ASA敏感的哮喘患者中诱发哮喘的可能性较小,但在这些患者中可能偶尔会发生交叉反应。此类反应较轻,用β2激动剂易于治疗。